Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person UniProt:P01116 KRAS
| Class:Id | ReferenceGeneProduct:62720 |
|---|---|
| _chainChangeLog | initiator methionine:1 added on Sat February 7 2015;chain:1-186 added on Sat February 7 2015;chain:2-186 added on Sat February 7 2015;propeptide:187-189 added on Sat February 7 2015;initiator methionine:1 for 62720 removed on Fri Nov 03 2023;initiator methionine: for 62720 added on Fri Nov 03 2023;initiator methionine: for 62720 removed on Fri Aug 15 2025;initiator methionine:1 for 62720 added on Fri Aug 15 2025 |
| _displayName | UniProt:P01116 KRAS |
| _timestamp | 2026-02-20 22:03:14 |
| chain | chain:1-186 initiator methionine:1 chain:2-186 propeptide:187-189 |
| checksum | 973547B2E11C2C81 |
| comment | FUNCTION Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306).CATALYTIC ACTIVITY GTP + H2O = GDP + phosphate + H(+)ACTIVITY REGULATION Alternates between an inactive form bound to GDP and an active form bound to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765). Activated by a guanine nucleotide-exchange factor (GEF) and inactivated by a GTPase-activating protein (GAP) (PubMed:22711838). Interaction with SOS1 promotes exchange of bound GDP to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765).SUBUNIT Interacts with PHLPP (By similarity). Interacts (active GTP-bound form preferentially) with RGS14 (By similarity). Interacts (when farnesylated) with PDE6D; this promotes dissociation from the cell membrane (PubMed:23698361). Interacts with SOS1 (PubMed:22431598). Interacts (when farnesylated) with GPR31 (PubMed:28619714). Interacts with RAP1GDS1 (PubMed:20709748, PubMed:24415755). Interacts (active GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:35768504, PubMed:35830882, PubMed:35831509, PubMed:36175670). Interacts (GTP-bound form) with MAPKAP1/SIN1; inhibiting K-Ras/KRAS activity (PubMed:34380736, PubMed:35522713).SUBUNIT Interacts with GPR31; in a farnelysation-dependent manner.INTERACTION Isoforms differ in the C-terminal region which is encoded by two alternative exons (IVA and IVB).PTM Acetylation at Lys-104 prevents interaction with guanine nucleotide exchange factors (GEFs).PTM Palmitoylated at Lys-182, Lys-184 and Lys-185 (PubMed:29239724). Palmitoylation on lysine residues is promoted by palmitoylation at Cys-180 (PubMed:29239724). Lysine-depalmitoylation by SIRT2 promotes its localization to endomembranes in endocytic pathways (PubMed:29239724).PTM Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at Lys-170 in a non-degradative manner, leading to inhibit Ras signaling by decreasing Ras association with membranes.PTM (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin TcsL.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE KRAS mutations are involved in cancer development.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.SIMILARITY Belongs to the small GTPase superfamily. Ras family. |
| description | recommendedName: GTPase KRas ecNumber evidence="17 40"3.6.5.2 alternativeName: K-Ras 2 alternativeName: Ki-Ras alternativeName: c-K-ras alternativeName: c-Ki-ras component recommendedName: GTPase KRas, N-terminally processed /component |
| geneName | KRAS KRAS2 RASK2 |
| identifier | P01116 |
| isSequenceChanged | FALSE |
| keyword | 3D-structure Acetylation Alternative splicing Cardiomyopathy Cell membrane Cytoplasm Deafness Direct protein sequencing Disease variant Ectodermal dysplasia Glycoprotein GTP-binding Hydrolase Intellectual disability Isopeptide bond Lipoprotein Membrane Methylation Nucleotide-binding Palmitate Prenylation Proteomics identification Proto-oncogene Reference proteome Ubl conjugation |
| modified | [InstanceEdit:9836292] Weiser, Joel, 2023-05-25 [InstanceEdit:9852000] Weiser, Joel, 2023-11-03 [InstanceEdit:9917590] Weiser, Joel, 2024-08-09 [InstanceEdit:9926675] Weiser, Joel, 2024-11-03 [InstanceEdit:9939033] Weiser, Joel, 2025-02-21 [InstanceEdit:9963647] Weiser, Joel, 2025-08-15 [InstanceEdit:9983091] Weiser, Joel, 2026-02-20 |
| name | KRAS |
| referenceDatabase | [ReferenceDatabase:2] UniProt |
| referenceGene | [ReferenceDNASequence:8990934] ENSEMBL:ENSG00000133703 KRAS [Homo sapiens] |
| secondaryIdentifier | RASK_HUMAN A8K8Z5 B0LPF9 P01118 Q96D10 |
| sequenceLength | 189 |
| species | [Species:48887] Homo sapiens |
| (isoformParent) | [ReferenceIsoform:152763] UniProt:P01116-2 KRAS [Homo sapiens] [ReferenceIsoform:402244] UniProt:P01116-1 KRAS [Homo sapiens] |
| (referenceEntity) | [EntityWithAccessionedSequence:62719] KRAS [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802292] KRAS D153V [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802331] KRAS G12C [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802333] KRAS G12D [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802354] KRAS G12V [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802359] KRAS G13D [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802434] KRAS Q61H [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802472] KRAS T58I [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:6802480] KRAS V14I [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:9647762] proKRAS [cytosol] [Homo sapiens] |
| (referenceSequence) | [ReplacedResidue:6802290] L-aspartic acid 153 replaced with L-valine [ReplacedResidue:6802328] glycine 12 replaced with L-cysteine [ReplacedResidue:6802332] glycine 12 replaced with L-aspartic acid [ReplacedResidue:6802355] glycine 12 replaced with L-valine [ReplacedResidue:6802357] glycine 13 replaced with L-aspartic acid [ReplacedResidue:6802439] L-glutamine 61 replaced with L-histidine [ReplacedResidue:6802473] L-threonine 58 replaced with L-isoleucine [ReplacedResidue:6802482] L-valine 14 replaced with L-isoleucine [ModifiedResidue:9647792] S-farnesyl-L-cysteine at 186 [ModifiedResidue:9647800] S-farnesyl-L-cysteine methyl ester at 186 |
| [Change default viewing format] | |
No pathways have been reviewed or authored by UniProt:P01116 KRAS (62720)
